Symposium | Practical considerations when sequencing novel agents and managing AEs with BCMA-directed therapies
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM).
The session covered mechanisms of resistance with BCMA-targeted therapies; the impact of prior exposure to BCMA-directed therapies; the main differences…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.